drugset
drugset / Trial / NCT00550225

Succinate Salt Version of GSK961081 for Healthy Volunteers

NCT00550225 ↗

Phase 1 Completed 18 enrolled Theravance Biopharma GlaxoSmithKline · collab
RandomizedCrossoverTreatment

Summary

Salt Bridging study for GSK961081

Timeline

Start
2007-11-29
Primary completion
2008-01-08
Completion
2008-01-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Batefenterol Small molecule 300 ug Inhaled
Subject Batefenterol Small molecule 900 ug Inhaled
Subject Batefenterol Small molecule 1500 ug Inhaled

Indications

chronic obstructive pulmonary disease